1. We examined the effects of endogenous @entity1421 ( @entity1421 ) on the production of @entity650 ( @entity650 ), @entity6824 ( @entity6824 ), and @entity7 ( @entity7 ) by @entity1356 ( @entity1356 )-stimulated @entity1 synovial fibroblasts. 2. @entity8228 (1 microM), a cyclo-oxygenase-2 (COX-2) inhibitor, inhibited @entity650 and @entity7 production (35+/-4% and 26+/-2%, respectively) but enhanced @entity6824 production (38+/-4%) by @entity1356 (1 ng ml(-1)) in synovial fibroblasts isolated from @entity1 with @entity571 ( @entity571 ) and @entity309 ( @entity309 ). Exogenous @entity1421 completely abolished the effects of @entity8228 on the production of each mediator by @entity571 fibroblasts stimulated with @entity1356 . 3. 8-Bromo @entity1919 and @entity5393 , @entity1919 analogues, mimicked the effects of @entity1421 on @entity650 , @entity6824 , and @entity7 production by @entity571 fibroblasts. 4. The EP(2) selective receptor agonist @entity56264 (2 nM) and the EP(4) selective receptor agonist @entity69446 (2 or 20 nM), but not the EP(1) selective receptor agonist @entity39947 (1 microM) and the EP(3) selective receptor agonist @entity56263 (1 microM), replaced the effects of @entity1421 on @entity650 , @entity6824 , and @entity7 production by @entity571 and @entity309 fibroblasts stimulated with @entity1356 in the presence of @entity8228 . 5. Both @entity571 and @entity309 fibroblasts expressed mRNA encoding EP(2) and EP(4) but not EP(1) receptors. In addition, up-regulation of EP(2) and EP(4) receptor mRNAs was observed at 3 h after @entity1356 treatment. 6. These results suggest that endogenous @entity1421 regulates the production of @entity650 , @entity6824 , and @entity7 by @entity1356 -stimulated @entity1 synovial fibroblasts through the activation of EP(2) and EP(4) receptors with increase in @entity1919 .

Regulation by @entity1421 of the production of @entity650 , @entity6824 , and XXXX in @entity1 synovial fibroblasts.

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity650 :: ('3569', 'Gene') :: ['IL-6', 'interleukin-6'] @entity5393 :: ('MESH:D003994', 'Chemical') :: ['dibutyryl cyclic AMP'] @entity571 :: ('MESH:D010003', 'Disease') :: ['osteoarthritis', 'OA'] @entity56264 :: ('MESH:C499423', 'Chemical') :: ['ONO-AE1-259'] @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor', 'VEGF'] @entity1356 :: ('3553', 'Gene') :: ['interleukin-1beta', 'IL-1beta'] @entity1421 :: ('MESH:D015232', 'Chemical') :: ['prostaglandin E(2)', 'PGE(2)'] @entity56263 :: ('MESH:C121546', 'Chemical') :: ['ONO-AE-248'] @entity1919 :: ('MESH:D000242', 'Chemical') :: ['cyclic AMP'] @entity69446 :: ('MESH:C461399|MESH:C561493', 'Chemical') :: ['ONO-AE1-329'] @entity39947 :: ('MESH:C500045', 'Chemical') :: ['ONO-DI-004'] @entity6824 :: ('1435', 'Gene') :: ['M-CSF', 'macrophage colony stimulating factor'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA'] @entity8228 :: ('MESH:C080955', 'Chemical') :: ['NS-398']
@entity7 :: (7422,Gene) :: ['vascular endothelial growth factor']
